Volume 25, Issue 5 (December & January 2022)                   J Arak Uni Med Sci 2022, 25(5): 10-19 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dalili N, Pour-rezagholi F, Mousavi M, Alinezhad M, Ashrafi S. Comparison the efficacy and safety of denovo Everolimus plus low dose cyclosporine with the standard protocol of cyclosporin plus cellcept in prevention of CMV and BK virus infection ,6 month and one year graft survival in kidney transplant recipient. J Arak Uni Med Sci 2022; 25 (5) :10-19
URL: http://jams.arakmu.ac.ir/article-1-7289-en.html
1- Department of Nephrology, Labbafinezhad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , nooshindalili4@gmail.com
2- Department of Nephrology, Labbafinezhad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Shahid Beheshti Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (182 Views)
Introduction: Years after the first successful kidney transplant, there are still many questions about the best immunosuppression regimen for these patients. Various studies have shown that long-term use of calcineurin inhibitor drugs can be associated with chronic nephrotoxicity and lead to irreversible damage to the transplanted organ. Therefore, the goal is to use immunosuppressive drugs and reduce the dose of calcineurin inhibitors as much as possible without increasing the risk of transplant rejection. This study aims to compare renal function, the rate of viral infections, and the occurrence of rejection after kidney transplantation in patients on two different treatment regimens including everolimus plus a low dose of calcineurin inhibitor against the standard protocol of calcineurin inhibitor along with mycophenolic acid in 60 kidney transplanted patients.
Methods: This clinical trial was conducted at Labbafinejad Hospital in Tehran between 2018-2019 on 60 kidney transplant patients aged 18 to 65 years and for 12 months.
Results: In terms of kidney function status based on GFR, except for the first month (P=0.02), there was no significant difference between the two groups in any of the time periods (P>0.05). Also, there was no statistically significant difference between the two study groups in terms of hospitalization length after transplantation and re-hospitalization during the study (P>0.05). 
Conclusions: The results of this study showed that the everolimus regimen and low dose of calcineurin inhibitor can be used de novo in transplant patients without increasing the risk of rejection in them and at the same time it may be able to reduce the incidence of viral infections after transplantation.
 
Full-Text [PDF 809 kb]   (115 Downloads)    
Type of Study: Original Atricle | Subject: Orology
Received: 2022/10/3 | Accepted: 2023/09/21

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb